EE200200214A - Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks - Google Patents
Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviksInfo
- Publication number
- EE200200214A EE200200214A EEP200200214A EEP200200214A EE200200214A EE 200200214 A EE200200214 A EE 200200214A EE P200200214 A EEP200200214 A EE P200200214A EE P200200214 A EEP200200214 A EE P200200214A EE 200200214 A EE200200214 A EE 200200214A
- Authority
- EE
- Estonia
- Prior art keywords
- mopidamol
- dipyridamole
- medicament
- prevention
- manufacture
- Prior art date
Links
- 102000009123 Fibrin Human genes 0.000 title 1
- 108010073385 Fibrin Proteins 0.000 title 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title 1
- 229960002768 dipyridamole Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229950003499 fibrin Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000004089 microcirculation Effects 0.000 title 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 title 1
- 229950010718 mopidamol Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99121121A EP1093814A1 (en) | 1999-10-22 | 1999-10-22 | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
PCT/EP2000/010123 WO2001030353A1 (en) | 1999-10-22 | 2000-10-14 | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200214A true EE200200214A (et) | 2003-06-16 |
Family
ID=8239263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200214A EE200200214A (et) | 1999-10-22 | 2000-10-14 | Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks |
Country Status (27)
Country | Link |
---|---|
US (2) | US20030149058A1 (xx) |
EP (2) | EP1093814A1 (xx) |
JP (1) | JP2003512431A (xx) |
KR (1) | KR20020040901A (xx) |
CN (2) | CN100411620C (xx) |
AR (1) | AR026197A1 (xx) |
AU (1) | AU784124B2 (xx) |
BG (1) | BG106609A (xx) |
BR (1) | BR0014946A (xx) |
CA (1) | CA2387486C (xx) |
CZ (1) | CZ20021487A3 (xx) |
EA (1) | EA200200448A1 (xx) |
EE (1) | EE200200214A (xx) |
HK (1) | HK1048597A1 (xx) |
HR (1) | HRP20020342A2 (xx) |
HU (1) | HUP0203249A3 (xx) |
IL (1) | IL148974A0 (xx) |
MX (1) | MXPA02003901A (xx) |
NO (1) | NO20021784D0 (xx) |
NZ (1) | NZ518525A (xx) |
PE (1) | PE20010747A1 (xx) |
PL (1) | PL354591A1 (xx) |
SK (1) | SK7112002A3 (xx) |
TR (1) | TR200201089T2 (xx) |
WO (1) | WO2001030353A1 (xx) |
YU (1) | YU30002A (xx) |
ZA (1) | ZA200203156B (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
DE10119680A1 (de) * | 2001-04-20 | 2002-11-14 | Boehringer Ingelheim Pharma | Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation |
DK1448205T3 (da) | 2001-10-05 | 2011-12-12 | Zalicus Inc | Kombinationer til behandling af immunoinflammatoriske sygdomme |
MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
CA2515266A1 (en) * | 2003-02-07 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
DE10306179A1 (de) * | 2003-02-13 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe |
EP1622621A2 (en) * | 2003-04-24 | 2006-02-08 | Boehringer Ingelheim International GmbH | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
JP2005060359A (ja) * | 2003-08-13 | 2005-03-10 | Boehringer Ingelheim Pharma Gmbh & Co Kg | 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンii拮抗薬の使用 |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
KR20070026577A (ko) | 2004-05-13 | 2007-03-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈소판 억제제 저항성 치료를 위한 디피리다몰의 용도 |
AU2005249794A1 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
DK1820506T3 (da) * | 2006-02-09 | 2008-07-07 | Teva Pharma | Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf |
US20100062066A1 (en) * | 2006-11-14 | 2010-03-11 | Acusphere, Inc | Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration |
EP2991634A1 (en) | 2013-04-30 | 2016-03-09 | Otitopic Inc. | Dry powder formulations and methods of use |
TW201503900A (zh) * | 2013-07-29 | 2015-02-01 | ren-zheng Lin | 增強治療急性中風之抗血小板藥物之遞送方法及其組合物 |
AU2016212527B2 (en) * | 2015-01-28 | 2019-03-07 | Realinn Life Science Limited | Compounds for enhancing PPARgamma expression and nuclear translocation and therapeutic use thereof |
KR101736832B1 (ko) | 2017-02-28 | 2017-05-17 | 초당약품공업 주식회사 | 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물 |
CN114432451B (zh) * | 2018-12-21 | 2024-02-09 | 广州市妇女儿童医疗中心 | 胃肠道疾病的免疫机制及治疗药物 |
CN111346228B (zh) * | 2018-12-21 | 2022-01-14 | 广州市妇女儿童医疗中心 | 胃肠道疾病的免疫机制及治疗药物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
DE2735830A1 (de) * | 1977-08-09 | 1979-03-01 | Thomae Gmbh Dr K | Antithrombotische arzneimittelkombination und verfahren zu ihrer herstellung |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
JPS6153271A (ja) * | 1984-08-24 | 1986-03-17 | Kaken Pharmaceut Co Ltd | ローダニン誘導体 |
EP0169465B1 (de) * | 1984-07-21 | 1990-02-28 | Hoechst Aktiengesellschaft | Kombinationspräparat aus Pyrimido-pyrimidinen und O-Acetylsalicylsäure bzw. deren pharmakologisch verträglichen Salzen und dessen Verwendung |
DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
US5242921A (en) * | 1988-04-27 | 1993-09-07 | Yale University | Compositions and methods for treating cutaneous hyperproliferative disorders |
SU1685450A1 (ru) * | 1989-03-10 | 1991-10-23 | Московский медицинский стоматологический институт им.Н.А.Семашко | Способ лечени скаленус-синдрома при шейном остеохондрозе |
IT1239064B (it) * | 1990-05-14 | 1993-09-20 | Fidia Spa | Uso terapeutico del dipiridamolo |
US5639482A (en) * | 1993-11-10 | 1997-06-17 | Crary; Ely J. | Composition for control and prevention of diabetic retinopathy |
CN1111985A (zh) * | 1994-05-06 | 1995-11-22 | 王志刚 | 阿司匹林与潘生丁复方多层片的制备方法 |
US5498613A (en) * | 1994-06-07 | 1996-03-12 | The University Of Southern California | Dipyridamole and analogs thereof in preventing adhesion formation |
US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
US5620409A (en) * | 1995-09-15 | 1997-04-15 | The Research Foundation Of State University Of New York | Method for inhibiting clot formation |
CN1152436A (zh) * | 1995-12-22 | 1997-06-25 | 王介明 | 一种治疗缺血性脑血管病和脑血栓的康复液及其制法 |
ID23908A (id) * | 1997-06-05 | 2000-05-25 | Lilly Co Eli | Metode pengobatan dari penyakit trombosis |
CN1108798C (zh) * | 1999-01-26 | 2003-05-21 | 广东药学院 | 一种治疗、预防血栓形成及中风的复方制剂及其制备方法 |
JP2003506394A (ja) * | 1999-08-10 | 2003-02-18 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法 |
EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
DE10011482B4 (de) * | 2000-03-09 | 2004-06-09 | Fresenius Hemocare Gmbh | Verfahren zum Herstellen eines Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Adsorbens und Verwendung des Adsorbens zur Herstellung eines Adsorbers |
US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
US20020187187A1 (en) * | 2001-04-21 | 2002-12-12 | Toshimitsu Ohki | Fast disintegrating meloxicam tablet |
US7064103B2 (en) * | 2002-01-04 | 2006-06-20 | Becton, Dickinson And Company | Binding protein as biosensors |
US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
CA2515266A1 (en) * | 2003-02-07 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
EP1622621A2 (en) * | 2003-04-24 | 2006-02-08 | Boehringer Ingelheim International GmbH | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
-
1999
- 1999-10-22 EP EP99121121A patent/EP1093814A1/en not_active Withdrawn
-
2000
- 2000-10-14 CN CNB008146756A patent/CN100411620C/zh not_active Expired - Fee Related
- 2000-10-14 EA EA200200448A patent/EA200200448A1/ru unknown
- 2000-10-14 KR KR1020027005042A patent/KR20020040901A/ko not_active Application Discontinuation
- 2000-10-14 SK SK711-2002A patent/SK7112002A3/sk not_active Application Discontinuation
- 2000-10-14 EE EEP200200214A patent/EE200200214A/xx unknown
- 2000-10-14 MX MXPA02003901A patent/MXPA02003901A/es unknown
- 2000-10-14 TR TR2002/01089T patent/TR200201089T2/xx unknown
- 2000-10-14 CA CA002387486A patent/CA2387486C/en not_active Expired - Fee Related
- 2000-10-14 CZ CZ20021487A patent/CZ20021487A3/cs unknown
- 2000-10-14 YU YU30002A patent/YU30002A/sh unknown
- 2000-10-14 AU AU12721/01A patent/AU784124B2/en not_active Ceased
- 2000-10-14 JP JP2001532773A patent/JP2003512431A/ja active Pending
- 2000-10-14 IL IL14897400A patent/IL148974A0/xx unknown
- 2000-10-14 HU HU0203249A patent/HUP0203249A3/hu unknown
- 2000-10-14 CN CNA2005101362547A patent/CN1823780A/zh active Pending
- 2000-10-14 BR BR0014946-2A patent/BR0014946A/pt not_active Expired - Fee Related
- 2000-10-14 WO PCT/EP2000/010123 patent/WO2001030353A1/en active IP Right Grant
- 2000-10-14 PL PL00354591A patent/PL354591A1/xx not_active Application Discontinuation
- 2000-10-14 EP EP00974393A patent/EP1225900A1/en not_active Withdrawn
- 2000-10-14 NZ NZ518525A patent/NZ518525A/en unknown
- 2000-10-20 AR ARP000105541A patent/AR026197A1/es not_active Suspension/Interruption
- 2000-10-20 PE PE2000001127A patent/PE20010747A1/es not_active Application Discontinuation
-
2002
- 2002-04-12 BG BG106609A patent/BG106609A/bg active Pending
- 2002-04-16 NO NO20021784A patent/NO20021784D0/no not_active Application Discontinuation
- 2002-04-18 HR HR20020342A patent/HRP20020342A2/hr not_active Application Discontinuation
- 2002-04-22 ZA ZA200203156A patent/ZA200203156B/xx unknown
-
2003
- 2003-02-06 HK HK03100835.6A patent/HK1048597A1/zh unknown
- 2003-02-27 US US10/376,072 patent/US20030149058A1/en not_active Abandoned
-
2007
- 2007-12-18 US US11/958,504 patent/US20080113934A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200214A (et) | Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks | |
EE200000253A (et) | Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks | |
EE200300212A (et) | Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks | |
EE05056B1 (et) | IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette nhtud ateroskleroosi ravimiseks ja/v?i ennetamiseks | |
EE200100618A (et) | Dieet- või farmatseutiline kompositsioon kasutamiseks hüperoksaluuria vältimiseks või raviks | |
PT1147114E (pt) | Novos aralquilaminas de espirofuropiridinas uteis em terapia. | |
AU4583601A (en) | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | |
EE200200274A (et) | Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon | |
DE60018978D1 (de) | Benutzerauthentifiezierung in medizinischen systemen | |
DK1204410T3 (da) | Farmaceutisk doseringsform med flere komponenter | |
MXPA03005731A (es) | Articulo absorbente que tiene tratamientos medicinales liberables. | |
ID30116A (id) | Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya | |
EE200100179A (et) | Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks | |
NO20005179D0 (no) | Medikament behandling | |
ID26612A (id) | Turunan-turunan siklobutena, pembuatannya dan penggunaan-penggunaan terapinya | |
EE200300363A (et) | N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks | |
DE69941825D1 (de) | Arzneistoffhaltiger kaugummi, dessen herstellungsverfahren und so erhaltene tablette | |
NO20023448D0 (no) | Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin | |
NO20032006L (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser | |
ZA200007111B (en) | Methods and devices for providing prolonged drug therapy. | |
MXPA03003032A (es) | Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. | |
EE200200605A (et) | Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks | |
DE69934902D1 (de) | Medikament gegen drogenabhängigkeit | |
NO990949D0 (no) | Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS | |
HUP0300717A3 (en) | Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |